Advertisement

EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases

  • Jan Tennvall
  • Boudewijn Brans
Guidelines

Abstract

Introduction

32P phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom 32P is the most optimal treatment option, an assertion supported by two large studies with long follow-up.

Purpose

The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for 32P phosphate therapy.

Keywords

Guidelines Nuclear medicine 32P phosphate Polycythaemia vera Essential thrombocythaemia Radionuclide therapy 

References

  1. 1.
    Najean Y, Rain JD for the French Polycythemia Study Group. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 1997;89(7):2319–27.PubMedGoogle Scholar
  2. 2.
    Brandt L, Anderson H. Survival and risk of leukaemia in polycythemia vera and essential thrombocythemia treated with oral radiophosphorus. Eur J Haematol 1995;54(1):21–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Fruchtman SM. Treatment paradigms in the management of myeloproliferative disorders. Semin Hematol 2004;41 (2 suppl 3):18–22.CrossRefPubMedGoogle Scholar
  4. 4.
    Barbui T. The leukaemia controversy in myeloprolifertive disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 2004;41 (2 Suppl 3):15–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide Study Group. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leukemia Res 2005;29:481–91.CrossRefGoogle Scholar

Copyright information

© EANM 2007

Authors and Affiliations

  1. 1.Department of OncologyLund University HospitalLundSweden
  2. 2.Department of Nuclear MedicineUniversity Medical CentreMaastrichtThe Netherlands

Personalised recommendations